Journal: Blood cancer journal
This multicenter retrospective study evaluated talquetamab, a first-in-class GPRC5DxCD3 bispecific antibody, in 114 heavily pretreated relapsed/refractory multiple myeloma (RRMM) patients.
All patients were triple-class refractory, with 79% penta-refractory and 65% having received prior BCMA-targeted therapy.
Key findings included:
- 73% overall response rate
- 26% complete responses
- 26% very good partial responses
- Median progression-free survival of 10 months
- Six-month progression-free and overall survival rates of 56% and 86%, respectively
Common toxicities:
- 54% cytokine release syndrome
- 27% infections
- 9.8% neurotoxicity
Notable safety concerns included:
- Significant weight loss (mean 8.8% at 6 months)
- Grade ≥3 infections in 18% of patients
- 61% receiving intravenous immunoglobulin
The study supports talquetamab’s efficacy in a difficult-to-treat RRMM population while emphasizing the need for vigilant monitoring and supportive care.